# Copanlisib Pharmacodynamic Study

> **NCT02155582** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 63 (actual)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Copanlisib (BAY80-6946)

## Key facts

- **NCT ID:** NCT02155582
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-12
- **Primary completion:** 2016-10-04
- **Final completion:** 2017-03-16
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2017-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02155582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02155582, "Copanlisib Pharmacodynamic Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02155582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*